hmpl-689
Showing 1 - 5 of 5
Relapsed/Refractory Lymphoma Trial in Shanghai (tazemetostat, HMPL-689)
Not yet recruiting
- Relapsed/Refractory Lymphoma
- tazemetostat
- HMPL-689
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiaotong University School of Medicine
Feb 2, 2023
Lymphomas Trial in Wuhan, Guangzhou, Shanghai (HMPL-689)
Active, not recruiting
- Lymphomas
- HMPL-689
-
Wuhan, Hubei, China
- +2 more
Sep 8, 2022
Lymphoma Trial in Worldwide (HMPL-689)
Active, not recruiting
- Lymphoma
- HMPL-689
-
Anaheim, California
- +26 more
Jan 11, 2023
Marginal Zone Lymphoma, Follicular Lymphoma Trial in China (HMPL-689)
Recruiting
- Marginal Zone Lymphoma
- Follicular Lymphoma
- HMPL-689
-
Hefei, Anhui, China
- +35 more
Jun 7, 2021
Healthy Volunteers Trial in Melbourne (HMPL-689, HMPL-689 )
Completed
- Healthy Volunteers
- HMPL-689
- HMPL-689 placebo
-
Melbourne, Victoria, AustraliaNucleus Network
Aug 15, 2017